Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1...
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders
About this item
Full title
Author / Creator
Publisher
United States: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor-nonbinding anti-CD3 monoclonal antibody, reduces the decline in C-peptide levels in patients with T1D 2 years after diseas...
Alternative Titles
Full title
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3806618
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3806618
Other Identifiers
ISSN
0012-1797
E-ISSN
1939-327X
DOI
10.2337/db13-0345
